The company received FDA and Health Canada approval for the clinical trial earlier in 2008.
The Phase II trial will be an international, multi-center, randomized, controlled, open-label study assessing the efficacy and safety of CTCE-9908 that will include up to 132 patients with liver cancer.
The company also announced that Fundamental Research Corporation has initiated analyst coverage of the company.
Walter Korz, president and CEO of Chemokine Therapeutics, said: “Liver cancer is more prevalent in the Asian communities and working with Dr Ronnie Poon, principal investigator for Hong Kong, will help to expedite the patient recruitment process.”